Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells

Programmed cell death-ligand 1 (PD-L1) protein expression is one of the most extensively studied biomarkers in patients with non-small cell lung cancer (NSCLC). However, there is scarce information regarding its association with distinct adenocarcinoma subtypes. This study evaluated the frequency of...

Full description

Saved in:
Bibliographic Details
Published in:Pathology oncology research 2021-04, Vol.27, p.597499-597499
Main Authors: Cruz-Rico, Graciela, Avilés-Salas, Alejandro, Popa-Navarro, Xitlally, Lara-Mejía, Luis, Catalán, Rodrigo, Sánchez-Reyes, Roberto, López-Sánchez, Dennis, Cabrera-Miranda, Luis, Aquiles Maldonado-Martínez, Héctor, Samtani-Bassarmal, Suraj, Arrieta, Oscar
Format: Article
Language:English
Subjects:
Adenocarcinoma of Lung - classification
Adenocarcinoma of Lung - genetics
Adenocarcinoma of Lung - metabolism
Adenocarcinoma of Lung - pathology
Adult
Aged
Aged, 80 and over
Antigens
Apoptosis
B7-H1 Antigen - genetics
B7-H1 Antigen - metabolism
Biomarkers
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Cancer
Carcinoma, Non-Small-Cell Lung - classification
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
Cell death
Chemotherapy
Female
Follow-Up Studies
Humans
Immunohistochemistry
Immunotherapy
Ligands
Lung cancer
Lung Neoplasms - classification
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Male
Medical prognosis
Medical records
Metastasis
Middle Aged
Mutation
Patients
Prognosis
Retrospective Studies
Society Journal Archive
Software
Survival Rate
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Programmed cell death-ligand 1 (PD-L1) protein expression is one of the most extensively studied biomarkers in patients with non-small cell lung cancer (NSCLC). However, there is scarce information regarding its association with distinct adenocarcinoma subtypes. This study evaluated the frequency of PD-L1 expression according to the IASLC/ATS/ERS classification and other relevant histological and clinical features. PD-L1 expression was assessed by immunohistochemistry (IHC). According to its positivity in tumor cells membrane, we stratified patients in three different tumor proportions score (TPS) cut-off points: a)
ISSN:1532-2807
1219-4956
1532-2807
DOI:10.3389/pore.2021.597499